Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
2.930
+0.145 (5.21%)
Nov 20, 2024, 4:00 PM EST - Market closed
Company Description
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel.
It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023.
Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Scinai Immunotherapeutics Ltd.
| Country | Israel |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Amir Reichman |
Contact Details
Address: Jerusalem BioPark , 2nd floor Jerusalem Israel | |
| Phone | 972 8 930 2529 |
| Website | scinai.com |
Stock Details
| Ticker Symbol | SCNI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611747 |
| ISIN Number | US09073Q2049 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Amir Reichman M.B.A., M.Sc. | Chief Executive Officer and Director |
| Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Dr. Dalit Weinstein Fischer Ph.D. | Chief Technology Officer |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Scientist |
| Liat Halpert | Head of Business Development and Sales |
| Merav Kamensky | Head of Quality Control |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 15, 2024 | 6-K | Report of foreign issuer |
| Sep 26, 2024 | 6-K | Report of foreign issuer |
| Sep 9, 2024 | 6-K | Report of foreign issuer |
| Aug 29, 2024 | 6-K | Report of foreign issuer |
| Aug 21, 2024 | 6-K | Report of foreign issuer |
| Aug 20, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 20, 2024 | 6-K | Report of foreign issuer |
| Aug 15, 2024 | 6-K | Report of foreign issuer |
| Aug 13, 2024 | 6-K | Report of foreign issuer |